Condition: Non Muscle Invasive Bladder Cancer · High-grade Ta/ T1 Papillary Disease Bladder Cancer · Sponsor: Lepu Biopharma Co., Ltd.
This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.
This description comes directly from the study's public registry record.
Program Director · 86-21-61637960 · clinicaltrials@lepubiopharma.com
Always discuss trial participation with your own doctor first.
| Peking University First Hospital (First Clinical Medical School of Peking University) | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| The Affiliated Drum Tower Hospital of Nanjing University Medical School | Nanjing, Jiangsu, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
| The Second Hospital of Tianjin Medical University | Tianjin, Tianjin Municipality, China | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07283835